Velafermin
Velafermin is a recombinant human fibroblast growth factor-20 (rhFGF-20) that has been investigated for its potential use in the prevention and treatment of oral mucositis, a common and often debilitating side effect of cancer therapy, particularly in patients undergoing hematopoietic stem cell transplantation.
Mechanism of Action[edit | edit source]
Velafermin functions by promoting the proliferation and differentiation of epithelial cells. As a member of the fibroblast growth factor family, it plays a crucial role in tissue repair and regeneration. The drug is designed to enhance the healing of the mucosal lining of the mouth, which can be damaged by chemotherapy and radiation therapy.
Clinical Development[edit | edit source]
Velafermin has undergone several phases of clinical trials to evaluate its safety and efficacy. Early-phase studies have shown promise in reducing the incidence and severity of oral mucositis in patients receiving high-dose chemotherapy. However, further studies are needed to confirm these findings and to establish optimal dosing regimens.
Potential Benefits[edit | edit source]
The primary benefit of Velafermin is its potential to reduce the severity and duration of oral mucositis, thereby improving the quality of life for patients undergoing cancer treatment. By mitigating this side effect, Velafermin may also allow patients to maintain their planned treatment schedules without interruption.
Side Effects[edit | edit source]
As with any therapeutic agent, Velafermin may have side effects. Commonly reported adverse effects include mild to moderate injection site reactions. The safety profile of Velafermin continues to be evaluated in ongoing clinical trials.
Regulatory Status[edit | edit source]
As of the latest updates, Velafermin is not yet approved for general clinical use and remains an investigational drug. Researchers continue to study its effects in various clinical settings to better understand its potential applications and limitations.
Also see[edit | edit source]
- Oral mucositis
- Fibroblast growth factor
- Cancer therapy side effects
- Hematopoietic stem cell transplantation
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
